ricorfotide vedotin

**Ricorfotide vedotin (CBP-1008, Rico-V)** is a first-in-class dual-ligand **small molecule-drug conjugate (Bi-XDC)** developed by **Coherent Biopharma** using their proprietary Bi-XDC platform. It features two peptide ligands targeting **folate receptor alpha (FRα)** and **TRPV6** (an oncochannel overexpressed in tumors), conjugated to **MMAE (monomethyl auristatin E)**, a microtubule inhibitor payload, enabling tumor-specific delivery and cytotoxicity independent of FRα expression levels. With a low molecular weight of ~3.4 kDa (1/50th of typical ADCs), it is fully chemically synthesized for cost-effective manufacturing. It has demonstrated strong efficacy in platinum-resistant ovarian cancer (PROC) with ORR, DCR, and OS superior to historical standards, favorable safety (mild-moderate AEs, no ocular toxicity, minimal neuropathy), and activity in breast and endometrial cancers; it holds **Fast Track** designation in the US and is advancing to **Phase 3** in China for PROC and triple-negative breast cancer.

Other names

ricorfotide vedotin